<DOC>
	<DOCNO>NCT00230282</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy combination fludarabine cyclophosphamide previously untreated CLL patient . Participants receive fludarabine cyclophosphamide day 1 , 2 , 3 six 28-day cycle .</brief_summary>
	<brief_title>Phase 2 Fludarabine , Cytoxan FCCAM &lt; Alemtuzumab &gt; Untreated B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This single-arm study evaluate safety efficacy combination fludarabine 25 mg/m2/d IV cyclophosphamide 250 mg/m2/d SC previously untreated CLL patient . Participants receive fludarabine cyclophosphamide day 1 , 2 , 3 six 28-day cycle , follow no-treatment rest period ( observation ) 3 12 week . Responders enter no-treatment rest period ( observation ) 3 8 week , depend status , continue follow-up on-study receive Campath state 3 mg/day dose adjust maximum tolerated dose .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>≥ age 18 Karnofsky performance status 60 % Confirmed immunohistological diagnosis Chronic Lymphocytic Leukemia ( CLL ) Rai Stage I IV follow : Advanced stage disease ( Rai Stage III IV , modify Rai High Risk ) OR Patients Rai Stage I II ( Modified Rai IntermediateRisk ) disease must indication therapy base 1996 NCI revise criterion active disease follow : Any one following diseaserelated symptom : 1 . Weight loss ≥ 10 % body weight within previous 6 month 2 . Extreme fatigue 3 . Fever great 100.5° F ≥ 2 week without evidence infection 4 . Night sweat without evidence infection Evidence progressive marrow failure base development worsen anemia thrombocytopenia Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid therapy Massive ( &gt; 6 cm leave costal margin ) progressive splenomegaly Bulky ( &gt; 10 cm cluster ) progressive lymphadenopathy Progressive lymphocytosis &gt; 50 % increase 2 month , anticipate double time &lt; 6 month Patients immunoglobulin VH gene unmutated nucleotide sequence configuration , define ≥ 98 % homology near germline counterpart Serum creatinine ≤ 2x upper limit normal Total serum bilirubin ≤ 2x upper limit normal . AST ≤ 2x upper limit normal . ALT ≤ 2x upper limit normal . Signed write informed consent Prior pharmacological treatment CLL Past history anaphylaxis follow exposure monoclonal antibody Active secondary malignancy history malignant disease ( CLL nonmelanoma skin cancer ) within precede 5 year Any medical condition require systemic corticosteroid Active systemic infection Major systemic illness ( include Coombs positivity active hemolysis ) would , opinion investigator , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result HIV positive serologic test Pregnant nursing female Unwilling/unable practice acceptable form contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>